<div>In this episode, Joshua K. Sabari, MD, discusses the FDA approval of amivantamab plus chemotherapy as a first-line treatment for patients with <em>EGFR</em> exon 20 insertion mutation-positive non-small cell lung cancer.</div>

In this episode, Joshua K. Sabari, MD, discusses the FDA approval of amivantamab plus chemotherapy as a first-line treatment for patients with EGFR exon 20 insertion mutation-positive non-small cell lung cancer.

In this episode, Joshua K. Sabari, MD, discusses the FDA approval of amivantamab plus chemotherapy as a first-line treatment for patients with <em>EGFR</em> exon 20 insertion mutation-positive non-small cell lung cancer.

S5 Ep5: FDA Approval Marks Amivantamab's Milestone in EGFR+ NSCLC

<div>Targeted Oncology brings you <em>Treating Together</em>, a podcast series designed to bring oncologists into meaningful, peer-driven conversations by focusing on real-world challenges, clinical relevance of emerging data, and bridging the gap between research and frontline oncology care across different cancer types.</div>

Science

Health & Fitness

Targeted Oncology brings you Treating Together, a podcast series designed to bring oncologists into meaningful, peer-driven conversations by focusing on real-world challenges, clinical relevance of emerging data, and bridging the gap between research and frontline oncology care across different cancer types.

Targeted Oncology brings you <em>Treating Together</em>, a podcast series designed to bring oncologists into meaningful, peer-driven conversations by focusing on real-world challenges, clinical relevance of emerging data, and bridging the gap between research and frontline oncology care across different cancer types.

Share S5 Ep5: FDA Approval Marks Amivantamab's Milestone in EGFR+ NSCLC

Sign up to save your podcasts

S5 Ep5: FDA Approval Marks Amivantamab's Milestone in EGFR+ NSCLC

S5 Ep5: FDA Approval Marks Amivantamab's Milestone in EGFR+ NSCLC

More shows like Treating Together

Planet Money

Interesting Times with Ross Douthat